Read More Pharma Industry News Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology? Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today. bySoujanya RaviApril 18, 2026